ISIS 301012

antisense oligonucleotide targeting apolipoprotein B-100 · Isis Pharmaceuticals (Ionis Pharmaceuticals)

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for ISIS 301012, covering 2016-08-03 to 2016-08-03. Get the full timeline:

Most recent: Clinical Trial Update: Dose-escalating Safety Study of ISIS 301012 in Homozygous Familial Hypercholesterolemia Subjects on Lipid Lowering Therapy [Phase 2]

See pricing